Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norbinaltorphimine is a highly selective, long-acting κ-opioid receptor antagonist and inverse agonist used exclusively in scientific research. It blocks the effects of κ-opioids, resulting in antidepressant-like and anxiolytic-like effects in animal models[1][6][11]. Norbinaltorphimine's mechanism involves cumulative and persistent inactivation of κ-opioid receptors, with doses producing pharmacological effects that last for weeks or months[1][7]. Unlike stimulants, it increases monoamines such as dopamine and noradrenaline in the prefrontal cortex, potentially relevant for ADHD, with a low risk of addiction[4]. It has been studied for potential in stress, anxiety, depression, and substance abuse relapse[5][13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norbinaltorphimine.